Some things are quite disappointing, patient recruitment for human trials and stelfonta revenue are at the top of that list.
Board meeting attendance is not one of them, every single director went to every single board meeting they were eligible to attend or invited to attend, 6 out of 6. One director missed two audit and risk committee meetings and one remuneration meeting that he was eligible to attend or invited to attend.
